Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

3.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.2K
Metastasis02:30

Metastasis

6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

6.0K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Selectins01:25

Selectins

4.1K
Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
4.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic disruption of <i>Capns1</i> impairs metastatic phenotypes in murine mammary carcinoma cells.

microPublication biology·2026
Same author

The delivery challenge of adeno-associated virus vector-based gene therapies for neurological diseases.

Frontiers in neuroscience·2026
Same author

Integrative functional genomics analysis identifies pleiotropic genes for vascular diseases.

Nature communications·2026
Same author

Bmpr2 Loss in the Vascular Endothelium Enhances Neoangiogenesis and Growth of Lung Metastatic Lesions in a Mouse Model of Breast Cancer.

Journal of cellular biochemistry·2025
Same author

<i>In Silico</i> Screening for Small Molecules to Alter Calpain Proteolysis through Modulating Conformation Changes Induced by Heterodimerization.

Journal of chemical information and modeling·2025
Same author

Quantification and structure-function analysis of calpain-1 and calpain-2 protease subunit interactions.

The Journal of biological chemistry·2025

Related Experiment Video

Updated: Jan 18, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

17.3K

Calpain-1 and Calpain-2 Promote Breast Cancer Metastasis.

Danielle Harper1,2, Jung Yeon Min1,2, James A MacLeod1,2

  • 1Department Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L3N6, Canada.

Cells
|September 13, 2025
PubMed
Summary

Targeting both calpain-1 and calpain-2 by disrupting their common regulatory subunit significantly reduces breast cancer metastasis. This finding supports the development of novel calpain inhibitors for cancer treatment.

Keywords:
CRISPR-Cas9breast cancercalpainmetastasismouse model

More Related Videos

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

3.0K
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

42.6K

Related Experiment Videos

Last Updated: Jan 18, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

17.3K
CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells
12:14

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

3.0K
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

42.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast cancer metastasis from stage I to IV drastically reduces survival rates.
  • Calpain-1 and calpain-2 expression correlates with cancer cell migration, invasion, and poor prognosis.

Purpose of the Study:

  • To determine which calpain isoform contributes to breast cancer metastasis.
  • To investigate the efficacy of targeting calpain-1 and calpain-2 for metastasis inhibition.

Main Methods:

  • CRISPR-Cas9 gene editing to individually knockout CAPN1 or CAPN2, and to knockout CAPNS1 (common regulatory subunit).
  • In vitro cell migration assays and in vivo metastasis assays using a mouse xenograft model of triple-negative breast cancer.
  • In vitro and in vivo testing of a cell-permeable calpastatin (CAST) peptide inhibitor.

Main Results:

  • Disrupting both calpain-1 and calpain-2 via CAPNS1 knockout reduced metastasis by 83.4% in vivo.
  • Individual CAPN1 or CAPN2 knockouts showed marginal effects on metastasis.
  • In vitro, a CAST peptide inhibitor reduced cell migration by 53.5%, but was ineffective in vivo due to rapid clearance.

Conclusions:

  • Calpain-1 and calpain-2 collectively drive breast cancer metastasis.
  • Targeting the common regulatory subunit (CAPNS1) or both isoforms is a promising strategy to abrogate metastasis.
  • Development of stable calpain inhibitors is warranted for effective in vivo cancer treatment.